top of page


Join date: Aug 20, 2021


The hematologic malignancies treatment market is expected to register a CAGR of 10.5% over the forecast period.

As most of the elective treatments were deferred in the outbreak of the COVID-19 pandemic, the hematologic malignancies treatment market is also expected to have impacted significantly. However, delayed treatment is not recommended for severe disease, especially those with acute leukemia and thus, necessary guidelines and measures have been put forth recently to allow hematologic malignancies treatment during the pandemic with all protective measures.


More actions
bottom of page